For the examples given for hip fracture risk, in some scenarios the risk is not exactly 3% but ranges between 2.9% and 3.2%.
Fracture risk in glucocorticoid-induced osteoporosis: Comment on the article by Grossman et al
Article first published online: 28 DEC 2011
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 1, page 157, January 2012
How to Cite
Watts, N. B. (2012), Fracture risk in glucocorticoid-induced osteoporosis: Comment on the article by Grossman et al. Arthritis Care Res, 64: 157. doi: 10.1002/acr.20651
- Issue published online: 28 DEC 2011
- Article first published online: 28 DEC 2011
- Accepted manuscript online: 3 OCT 2011 08:41AM EST
To the Editor:
Grossman and colleagues are to be commended for the work they put into the 2010 American College of Rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis (Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515–26). In categorizing risk based on major fractures (high risk is defined as ≥20% 10-year risk for major fractures) as calculated using the FRAX tool (FRAX. WHO Fracture Risk Assessment Tool. URL: http://www.shef.ac.uk/FRAX/), the authors appear to have overlooked the fact that, in FRAX, glucocorticoid use increases hip fracture risk more than major fracture risk. This results in patients being at high risk based on hip fractures (high risk is defined as ≥3% 10-year risk for hip fractures), but at intermediate risk based on major fractures (10–20% 10-year risk), and would likely result in patients being at intermediate risk for hip fracture, but low risk for a major fracture. For example, a 50-year-old white woman with no risk factors other than glucocorticoid use would be at high risk for hip fracture with a T score of −2.6, but would only reach the high-risk threshold for major fractures with a T score of −3.6.
Table 1 shows, as a function of age, T scores for women and men with a body mass index of 25 kg/m2 and no other risk factors in FRAX, at which hip and major fractures would register a high risk (using FRAX version 3.3). In each case, high risk is reached at a lower T score for hip fracture than for major fractures.
|Hip fracture (2.9–3.2%)||−2.6||−2.4||−2.2||−2.0||−1.6||−1.1||−0.6||−0.2||−0.3|
|Major fracture (=20%)||−3.6||−3.1||−2.6||−2.4||−2.1||−1.9||−1.3||−1.3||−2.2|
|Hip fracture (2.9–3.2%)||−2.3||−2.1||−2.0||−1.8||−1.5||−1.0||−1.3||−0.2||−0.6|
|Major fracture (=20%)||−3.4||−3.1||−2.9||−2.9||−2.8||−2.8||−2.7||−2.9||−4.0|
|African American women|
|Hip fracture (2.9–3.2%)||−3.2||−3.1||−2.9||−2.7||−2.5||−2.1||−1.7||−1.5||−1.7|
|Major fracture (=20%)||−4.4||−4.3||−4.1||−3.9||−3.7||−3.5||−3.2||−3.2||−3.9|
|African American men|
|Hip fracture (2.9–3.1%)||−2.9||−2.9||−2.8||−2.7||−2.6||−2.3||−1.9||−1.9||−2.4|
|Major fracture (=20%)||−4.3||−4.2||−4.3||−4.5||−4.6||−4.6||−4.6||−4.8||−6.1|
It is important to recognize that patients receiving glucocorticoids consistently reach high risk for hip fracture before they reach high risk for major fractures.
Dr. Watts is Director and Cofounder of and owns stock and/or holds stock options in OsteoDynamics, and he has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Amgen, Novartis, Warner Chilcott, Baxter, Bristol-Myers Squibb, Imagepace, Lilly, Medpace, Merck, Orexigen, and Pfizer/Wyeth, research support from Amgen, Merck, and NPS, and has served as a paid consultant with investment analysts on behalf of Guidepoint Global, GLG, and Leerink Swann.
Nelson B. Watts MD*, * University of Cincinnati, Cincinnati, Ohio.